Type 2 Diabetes Medication Market 2028 By Drug Class Inhibitors, Application, and Geography | The Insight Partners

report image

Type 2 Diabetes Medication Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-glucosidase Inhibitors, Sulfonylureas and Other Insulin Secretagogues, Biguanides, and SodiumGlucose Cotransporter 2 Inhibitors); Application (Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, and Others), and Geography

Report Code: TIPRE00024009 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Type 2 diabetes is a longterm disorder that affects the body's blood sugar level. Elevated blood sugar level (hyperglycemia) causes detrimental effects on the heart, kidneys, eyes, blood vessels, and nerves. Type 2 diabetes is characterized by the resistance of insulin and a relative shortage of insulin. Few common symptoms of type 2 diabetes include increased dehydration, sudden weight loss, and recurrent urination. Type 2 diabetes occurs because of obesity and lack of exercise. It can be prevented partially by eating properly, maintaining a normal weight, and exercising regularly. Type 2 diabetes is generally detected using the glycated hemoglobin test. This blood test indicates the average blood sugar level for the past two to three months. If the patient failed to maintain the target blood sugar level with diet and exercise, the doctor might prescribe diabetes medications that help lower insulin levels or insulin therapy.


The "Global Type 2 Diabetes Medication Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Type 2 Diabetes medication market with detailed market segmentation by drug class, application, and geography. The report provides key statistics on the market status of the leading Type 2 Diabetes medication market players and offers key trends and opportunities in the market.


    - Based on drug class, the global Type 2 Diabetes medication market is segmented into dipeptidyl peptidase-4 (dpp-4) inhibitors, glucagon-like peptide-1 (glp-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas and other insulin secretagogues, biguanides, sodiumglucose cotransporter 2 inhibitors.
    - On the basis of application, the market is segmented into glycemic control, cardiovascular safety, hypoglycemia avoidance, others.


    - Rise in the incidences of type 2 diabetes.
    - Rise in the support from government in the form of initiatives & programs for type 2 diabetes diagnosis & treatment.
    - Rise in geriatric population.
    - Change in lifestyle.
    - Increasing obesity population.


    - The high cost of diagnosis and treatment therapies for diabetes and the stringent regulations are the major restraining factor for this market.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Type 2 Diabetes medication market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

BThe report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Type 2 Diabetes medication market in these regions.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Get more information on this report :


The report covers key developments in the Type 2 Diabetes medication market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Type 2 Diabetes medication market are anticipated to lucrative growth opportunities in the future with the rising demand for Type 2 Diabetes medication in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Type 2 Diabetes medication market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    - Bayer AG
    - Abbott Laboratories, Inc.
    - GlaxoSmithKline
    - Eli Lilly and Co., PLC
    - Johnson & Johnson Services, Inc.
    - Merck & Co.
    - Pfizer Inc.
    - AstraZeneca, PLC
    - Becton, Dickinson and Co.
    - F. Hoffmann-La Roche Ltd

The Insight Partner's dediType 2 Diabetes medicationed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Bayer AG
2. Abbott Laboratories, Inc.
3. GlaxoSmithKline
4. Eli Lilly and Co., PLC
5. Johnson & Johnson Services, Inc.
6. Merck & Co.
7. Pfizer Inc.
8. AstraZeneca, PLC
9. Becton, Dickinson and Co.
10. F. Hoffmann-La Roche Ltd.
11. Sanofi Aventis A/S
12. Novo Nordisk
13. Chugai Pharmaceutical Co.
14. Bristol-Myers Squibb
15. Boehringer Ingelheim
16. Takeda
17. Novartis
18. Theracos
19. Lexicon Pharmaceuticals
20. Hua Medicine Shanghai Ltd
21. Tonghua Dongbao Pharmaceutical Co Ltd
22. Jiangsu Hengrui Medicine Co Ltd.
23. Sihuan Pharmaceutical Holdings Group Ltd
24. Biocon Ltd.
25. Oramed Pharamceuticals
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount